US Bancorp DE Sells 12,846 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

US Bancorp DE decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 51.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,016 shares of the biopharmaceutical company’s stock after selling 12,846 shares during the quarter. US Bancorp DE’s holdings in Amicus Therapeutics were worth $128,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Amicus Therapeutics by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 57,044 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 22,244 shares in the last quarter. abrdn plc increased its position in shares of Amicus Therapeutics by 9.1% during the third quarter. abrdn plc now owns 1,808,792 shares of the biopharmaceutical company’s stock valued at $19,318,000 after acquiring an additional 150,179 shares during the last quarter. Semanteon Capital Management LP bought a new stake in Amicus Therapeutics during the third quarter worth $1,131,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,884 shares during the last quarter. Finally, Legacy Capital Group California Inc. bought a new position in Amicus Therapeutics in the 3rd quarter valued at $206,000.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. This trade represents a 0.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Down 4.1 %

Shares of NASDAQ:FOLD opened at $9.68 on Friday. The firm has a fifty day moving average price of $11.00 and a two-hundred day moving average price of $10.61. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -28.47 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Analyst Ratings Changes

FOLD has been the topic of a number of research analyst reports. Morgan Stanley cut their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Bank of America increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.63.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.